Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

Machine learning models using data from digital inhalers can successfully predict COPD exacerbations up to 5 days in advance.

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

(ABC 6 News) — An air quality alert has been issued throughout the entirety of Minnesota heading into the weekend. According ...

The Minnesota Pollution Control Agency (MPCA) has issued an air quality alert for all of Minnesota. The alert runs until 6 ...

Plumes of Saharan dust are expected to sweep over Florida in the coming days, which can cause real problems for people with ...

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Topline results were announced from two phase 3 trials evaluating itepekimab, an anti-interleukin-33 monoclonal antibody, in former smokers with inadequately controlled chronic obstructive pulmonary ...

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...